2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. Src

Src

Src

Related Products

PDF 1.28 MB

Src family kinase (SFK) is a family of non-receptor tyrosine kinases including nine members: Src, Yes, Fyn, and Fgr, forming the SrcA subfamily, Lck, Hck, Blk, and Lyn in the SrcB subfamily, and Frk in its own subfamily. In immune cells, Src-family kinases (SFKs) have been implicated as critical regulators of a large number of intracellular signaling pathways. Src-family kinases (SFKs) occupy a proximal position in numerous signaling transduction cascades including those emanating from the T and B cell antigen receptors, Fc receptors, growth factor receptors, cytokine receptors, and integrins. In addition to these positive regulatory roles, Src-family kinases (SFKs) can also function as negative regulators of cellular signaling by phosphorylating immunoreceptor tyrosine-based inhibitory motifs (ITIMs) on inhibitory receptors, resulting in recruitment and activation of inhibitory molecules such as the phosphatases SHP-1 and SH2 containing 5′ inositol phosphatase (SHIP-1).

Src Isoform Specific Products:

Src Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-135216
    Antiproliferative agent-54
    		Inhibitor
    Antiproliferative agent-54 (Compound 6z) is the inhibitor for multiple kinases, such as ABL WT, B-RAF, EGFR, HCK, LYN A and SRC with IC50 of 6-50 nM. Antiproliferative agent-54 inhibits proliferation of several cancer cell, inhibits HUVEC and HepG2, with EC50 of 34 and 38 nM. Antiproliferative agent-54 exhibits good pharmacokinetic characteristics in rats.
    Antiproliferative agent-54
  • HY-175845
    Scr-IN-2
    		Inhibitor
    Scr-IN-2 is an effective c-Scr inhibitor with an IC50 of 302 nM. Scr-IN-2 exhibits nanomolar-level anti-breast cancer activity. Scr-IN-2 increases the level of ROS in cells, induces mitochondrial damage, G1 phase arrest, and apoptosis. Scr-IN-2 can be used in the research of breast cancer.
    Scr-IN-2
  • HY-162879
    FAK inhibitor 7
    		Inhibitor
    FAK inhibitor 7 is a type of FAK inhibitor with an IC50 value of 3.58 nM. FAK inhibitor 7 can inhibit the downstream signaling cascades of FAK (like Src and AKT), causing ovarian cancer cells to stall in the G0/G1 phase and induce cytotoxic autophagy. FAK inhibitor 7 can also suppress tumor metastasis and growth in ovarian cancer mice.
    FAK inhibitor 7
  • HY-162413
    (R)-LW-Srci-8
    		Inhibitor
    (R)-LW-Srci-8 is a selective covalent inhibitor of c-Src (IC50= 35.83 nM) that disrupts the autophosphorylation of c-Src by targeting its autophosphorylation site (Y419).
    (R)-LW-Srci-8
  • HY-127002A
    Squarunkin A hydrochloride
    		Inhibitor
    Squarunkin A hydrochloride is a potent and selective UNC119-cargo interaction inhibitor (IC50 of 10 nM for inhibiting the UNC119A-myristoylated Src N-terminal peptide interaction). Squarunkin A hydrochloride interferes with the activation of Src kinase in cells.
    Squarunkin A hydrochloride
  • HY-P1111A
    Lyn peptide inhibitor TFA
    		Inhibitor
    Lyn peptide inhibitor TFA is a potent and cell-permeable inhibitor of Lyn-coupled IL-5 receptor signaling pathway, while keeping other signals intact. Lyn peptide inhibitor TFA blocks Lyn activation and inhibits the binding of Lyn tyrosine kinase to βc subunit of IL-3/GM-CSF/IL-5 receptors. Lyn peptide inhibitor TFA can be used for study of  asthma, allergic, and other eosinophilic disorders.
    Lyn peptide inhibitor TFA
  • HY-175280
    Lck degrader-1
    		Degrader
    Lck degrader-1 (Compound 17) is a molecular glue degrader targeting lymphocyte-specific protein tyrosine kinase (LCK) (DC50=23.1 nM). Lck degrader-1 is promising for research of T-cell acute lymphoblastic leukemia (T-ALL).
    Lck degrader-1
  • HY-176194
    Antifibrotic agent 1
    		Inhibitor
    Antifibrotic agent 1 is an orally active anti-idiopathic pulmonary fibrosis (IPF) agent. Antifibrotic agent 1 effectively attenuates IPF-related processes, including TGF-β induced EMT and FMT processes, as well as pro-fibrotic M2 polarization. Antifibrotic agent 1 selectively inhibits CSF-1R, PDGFR-α and Src family kinases (SFKs), while sparing VEGFRs, FGFRs and Abl to minimize off-target toxicity. Antifibrotic agent 1 has potent anti-fibrotic activity in Bleomycin (BLM) (HY-108345)-induced pulmonary fibrosis mice model.
    Antifibrotic agent 1
  • HY-170971
    Src Inhibitor 4
    		Inhibitor
    Src Inhibitor 4 (Compound 18) is a derivative of KX-01 and an Src inhibitor. Src Inhibitor 4 can inhibit tumor cells, disrupt microtubules, and induce cell cycle arrest, apoptosis, and immunogenic cell death. After the introduction of phenolic or aniline functionality, Src Inhibitor 4 can serve as a payload attachment site for antibody-drug conjugates and has anti-tumor activity.
    Src Inhibitor 4
  • HY-100824
    PP2 Analog
    		Inhibitor
    PP2 Analog (compound 3) is a ATP-competitive Src family kinases inhibitor with the IC50 values of 0.22, 0.15, 2.68, and 7 aganist of lck (64-509), src , kdr, and tie-2.
    PP2 Analog
  • HY-176225
    BY13
    		Degrader
    BY13 is a SRC-3 PROTAC degrader with a DC50 of 0.031 μM. BY13 selectively blocks the ER signaling pathway over that of androgen receptor (AR)) through down-regulating ERα level. BY13 potently overcomes endocrine resistance in breast cancer by inducing cell cycle arrest in G1 phase and apoptosis, with superior effect over Fulvestrant (HY-13636). BY13 significantly inhibits the growth of drug-resistant breast tumors without obvious toxicity in LCC2 xenograft mice model. Pink: SRC-3 ligand (SI-2) (HY-101447); Blue: CRBN ligase ligand (HY-41547); Black: linker (HY-176226)
    BY13
  • HY-10181BR
    Dasatinib monohydrate (Standard)
    		Inhibitor
    Dasatinib (monohydrate) (Standard) is the analytical standard of Dasatinib (monohydrate). This product is intended for research and analytical applications. Dasatinib (BMS-354825) monohydrate is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib monohydrate inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively. Dasatinib monohydrate also induces apoptosis and autophagy.
    Dasatinib monohydrate (Standard)
  • HY-168187
    Src Inhibitor 3
    		Inhibitor
    Src Inhibitor 3 (Compound 7d) is a Src inhibitor with an IC50 of 285 nM. Src Inhibitor 3 inhibits HepG2 cells proliferative with an IC50 of 1.55 μM.
    Src Inhibitor 3
  • HY-175193
    N-Deshydroxyethyl Dasatinib-C3-NH2
    		Inhibitor
    N-Deshydroxyethyl Dasatinib-C3-NH2 is an Target Protein Ligand-Linker Conjugate that incorporates a ligand for LCK (HY-107447) and a PROTAC linker (HY-76667), which recruits E3 ligases. N-Deshydroxyethyl Dasatinib-C3-NH2 can be used for synthesis of PROTAC SJ11646 (HY-175281).
    N-Deshydroxyethyl Dasatinib-C3-NH2
  • HY-N0752R
    Scutellarein (Standard)
    		Inhibitor
    Scutellarein (Standard) is the analytical standard of Scutellarein. This product is intended for research and analytical applications. Scutellarein is a natural flavonoid compound with anti-inflammatory effects.
    Scutellarein (Standard)
  • HY-175298
    STAT-3/c-Src-IN-1
    		Inhibitor
    STAT-3/c-Src-IN-1 (Compound 12d) is a dual STAT-3 (IC50=0.844 μM) and c-Src (IC50=0.268 μM) inhibitor. STAT-3/c-Src-IN-1 blocks tumor cell proliferation, migration, and angiogenesis signaling pathways. STAT-3/c-Src-IN-1 exhibits potent anti-proliferative activity against melanoma (SK-MEL-2) and CNS cancer (SNB-75) cell lines (GI50=-5.75 μM and -5.63 μM), inducing tumor cell apoptosis via G0/G1 and G2/M phase cell cycle arrest. STAT-3/c-Src-IN-1 is promising for research of melanoma and glioblastoma.
    STAT-3/c-Src-IN-1
  • HY-P3773
    p60c-src substrate II
    p60c-src substrate II is an efficient pentapeptide substrate for the tyrosine kinase pp60c-src.
    p60c-src substrate II
  • HY-N0031R
    Plantamajoside (Standard)
    Plantamajoside (Standard) is the analytical standard of Plantamajoside. This product is intended for use in research and analytical applications. Plantamajoside is an orally active phenylpropanoid glycoside. Plantamajoside can be isolated from Plantago asiatica L.(Plantaginaceae). Plantamajoside inactivates NF-κB, PI3K/akt, induces Apoptosis, and improves Autophagy. Plantamajoside regulates MAPK, integrin-linked kinase/c-Src. Plantamajoside inhibits multiple cancers, improves lung and kidney damage. Plantamajoside has neuroprotective and anti-inflammatory effects.
    Plantamajoside (Standard)
  • HY-10209AR
    Masitinib mesylate (Standard)
    		Inhibitor
    Masitinib (mesylate) (Standard) is the analytical standard of Masitinib (mesylate). This product is intended for research and analytical applications. Masitinib mesylate (AB-1010 mesylate) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC50s=540/800 nM), Lyn (IC50= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib mesylate (AB-1010 mesylate) has anti-proliferative, pro-apoptotic activity and low toxicity.
    Masitinib mesylate (Standard)
  • HY-N7264R
    7α-Hydroxycholesterol (Standard)
    7α-Hydroxycholesterol is a cholesterol oxide and can serve as a biomarker for oxidative stress and lipid peroxidation. 7α-Hydroxycholesterol has cytotoxic and pro-inflammatory activities. 7α-Hydroxycholesterol can also inhibit sterol synthesis and reduce the activity of HMG-CoA reductase. 7α-Hydroxycholesterol can be used in the research of diseases such as diabetes and atherosclerosis.
    7α-Hydroxycholesterol (Standard)
Cat. No. Product Name / Synonyms Application Reactivity
Src Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.